VERISANTE TECHNOLOGY Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VERISANTE TECHNOLOGY

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: andre dallaire	8/16/2012 7:48:21 AM
	Read Replies (2) of 254

the answer that he gave me there are hard / real costs and opportunity costs the war in early cancer detection devices will be won by the one who lowers biopsy ratios and improves detection - IMO that will be verisante Pathology labs are overworked and short on staff and funds - a diagnosis must be double checked and sometimes triple checked. Devices that increase biopsy increase both costs and will not be adopted on a mass scale. Pathology also has a false positive / false negative factor that scares many - once this tech proves itself in the doctors office more accurate invitro versions will likely start to move into pathology departments as well to offer an objective second opinion apart from human eyes under the microscope..... just my thoughts.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next